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ABSTRACT 
Glaucoma is a term used for a group of diseases; associated with optic nerve damage which leads to loss of retinal ganglionic cells. 
The changes stimulated in the optic nerve head cause visual field restriction which may ultimately result in blindness. 
Conventionally, the drugs used in treatment are ocular anti-hypertensives and are available as eye drops. Challenges faced in ocular 
delivery of a drug reduce the efficacy of such formulations. In a disease like glaucoma which is a leading cause of irreversible 
blindness, effective delivery of drug to the site of absorption is paramount in order to prevent disease progression. The novel drug 
delivery systems have shown great promise in this regard. They have been developed with a viewpoint to improve ocular retention of 
therapeutic agents. Niosomes have been exploited well and have elicited a positive response. The review is aimed at bringing out 
facts about the disease including worldwide prevalence, types, treatment, its impact and also constraints in ocular drug delivery, drug 
delivery alternatives, and niosomes in particular with their composition, advantages and their potential in management of ocular 
hypertension. 
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INTRODUCTION 
Glaucoma is characterized by optic neuropathy, cupping 
and atrophy of optic disk, loss of peripheral vision and 
reduction in visual acuity at advanced stages. It has been 
heralded as one of the major causes of blindness around 
the world
1,2
. Global awareness regarding the disease is 
poor thus disease goes unnoticed usually until advanced 
stage has set in. The diagnosis and criteria set to discern 
the onset of disease has been variable thus complicating 
the scenario. The primary mode of management is 
maintaining the elevated (IOP) intraocular pressure at a 
permissible level where further damage of the nerves is 
prevented. For this, medications are prescribed that are 
instilled topically. The shortcoming of such treatment 
lies in the fact that conventional eye drops are unable to 
deliver a substantial amount of drug to the ocular tissue 
leading to reduced efficacy
3,4
. Newer delivery systems 
have been evaluated; of which niosomes offer many 
advantages such as, being able to deliver the drug for a 
prolonged period of time, increased stability against 
degradation and scope for surface modification which 
leads to enhanced efficacy, better penetration etc.,
4,5
. 
WORLDWIDE PREVALENCE 
According to the reports published in literature as of 
now close to 3.54% people over the age of 40 suffer 
from glaucoma around the globe and it presents as the 
leading cause of irreversible loss of sight
6
. Figures of 
close to 80 million people being affected by the disease 
by the year 2020, which is expected to  rise to 111 
million by end of 2040 have been reported
6, 7, 8
. 
Indian Scenario: It is estimated that in India alone the 
number of people with glaucoma is set to rise to 16 
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million by the end of 2020 as compared to 11.9 million 
as affected by both types of glaucoma by 2010
8
. The 
prevalence of any type of glaucoma in India was found 
to be 2.6% of which, (POAG) primary open angle 
glaucoma contributed 1.6% and (PACG) primary angle 
closure glaucoma 0.5%
9-11
. As the rise in cases of 
glaucoma is substantial, increased awareness of disease 
and better therapeutic options must be made available. 
TYPES OF GLAUCOMA 
Though many variants of the disease exist, the most 
common form is (OAG) open angle glaucoma followed 
by (ACG) angle closure glaucoma
1
. Other forms include 
secondary glaucoma, congenital glaucoma, etc.
12
. These 
forms may have either sudden onset or may preside over 
a long period of time and by any which way the damage 
caused to the nervous tissue of the eye is severe and 
leads to visual impairment. 
Treatment: Presently the treatment regimen constitutes 
use of medicinal agents to reduce the elevated IOP 
which also helps in delaying progression of the disease. 
Surgical procedures are resorted to when patient is 
unresponsive to medicinal agents
13
. Different classes of 
drugs available to manage IOP are listed below
14
: 
i. β-Blockers: The agents used are Timolol maleate, 
Betaxolol, Levobunolol, etc.,  these are plagued 
with cardiopulmonary side effects and central 
nervous system side effects.  
ii. Miotics: The agents used are Pilocarpine, 
Carbachol, etc., these present side effects related to 
blurred vision, near sightedness, reduced pupil size 
that affects night vision and parasympathomimetic 
side effects. 
iii. Sympathomimetics: The agents used are Dipivefrin, 
Epinephrine, etc., these present side effects in form 
of allergic symptoms and elevated blood pressure. 
iv. α2-Adrenergic Receptor Agonists: The agents used 
are Brimonidine tartrate and Apraclonidine, these 
present side effects that include allergic reactions 
such as blepharoconjunctivitis and elevated blood 
pressure etc. 
v. Carbonic Anhydrase Inhibitors: The agents used are 
Acetazolamide, Dorzolamide, etc., side effects 
associated with oral therapy are high which include 
frequent urination, aplastic anemia etc. 
vi. Prostaglandin Analogs: Their examples include 
Latanoprost, Bimatoprost, etc. These present side 
effects such as ocular irritation and upper 
respiratory tract symptoms. 
TRENDS ASSOCIATED WITH DISEASE 
A lot of studies have been conducted and the results 
have been used to estimate the pattern of the disease and 
the populations most affected by it. Some of the data 
related to glaucoma has been tabulated (Table 1). Risk 
factors and their attributes implicated in development of 
glaucoma have also been presented (Table 2).
 
Table 1: Trends Observed with Disease 
Factors  POAG PACG 
Global prevalence  3.05 % 0.5 % 
Ethnicity African descent Asian descent 
Age Above 40 years Above 40 years 
Gender Male predisposition Female predisposition 
Ocular condition Myopia, Ocular Hypertension Corneal thinning 
Diagnosis Tonometry Gonoscopy 
 
Ethnicity: As far as the trends are concerned, people 
with African ethnicity are more likely to develop open 
angle glaucoma
6-8,15-17
 whereas Asians are known to be 
greatly affected by PACG than white populations
12,18
. 
China might be the leader in most cases with angle 
closure glaucoma 47.5 % in total of all cases reported
8
.  
Age and Metabolic disorders: The increase in number 
of glaucoma cases worldwide especially in developing 
countries has also been attributed to the fact that a large 
segment of its population is aging. Those above the age 
of 70 have increased risk of the disease due to alteration 
in health owing to development of metabolic diseases 
simultaneously. In an analysis it was found that effect of 
age, varied with the geographical region and in people 
with European descent there was a steeper rise in 
glaucoma cases with a decade increase in age
8,19
. 
 
Table 2: Risk Factors Implicated in Disease Development: 
Risk factors Attributes  
Elevated Intraocular pressure
7,13,20 
Greater than 25 mm Hg 
Cup-to-disk ratio
15,20 
Greater than 0.3 
Age
6-8 
Over 40, higher incidence of those over 70 
Familial history of glaucoma
7,13,16 
Genetic predisposition 
Heritage
6-8,16-18 
African; Asians; Hispanic 
Ocular diseases
7,13 
Eye trauma, thinning in  central cornea, myopia or hyperopia 
Metabolic diseases
7,13 
Those suffering from diabetes, migraines, high blood pressure, poor circulation 
or other health problems 
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IMPACT OF GLAUCOMA 
It can be broadly divided into two parts where we can 
attribute it to quality of life associated with the disease 
and economic burden of the disease. 
 Quality of life: 
In a study published by WHO it was estimated that close 
to 5.2 million people would be blind due to glaucoma 
until 1990 accounting for 15% of total global 
blindness
20
. Given the steep rise in glaucoma cases 
worldwide and with aging population, it was later 
postulated that by 2010 8.4 million would be bilaterally 
blind of which POAG contributes to 4.5 million cases
8, 
21
. PACG though not widely reported has been 
responsible for about 50% of blindness caused by 
glaucoma
12
. Blindness not only impairs the person but 
also influences quality of life of that person. A lot of 
care needs to be given to such patients when loss of 
sight occurs. As people are unable to work on their own, 
it affects their mental well being; self esteem and might 
lead to depression
21
. 
 Economic burden: 
The costs incurred during treatment of glaucoma not 
only include the direct medical costs (i.e. those 
associated with medicines, physician fees etc.) but also 
indirect costs. The indirect costs can be identified as loss 
of days in work, lower productivity due to vision 
impairment and nursing charges, etc.,
21-22
. In a study 
conducted across Europe, it was found that costs 
incurred increased linearly with disease severity
19
. Also 
a patient may have to visit the physician 10 million or 
more times for follow up
22
, such high number of visits 
not only demands a lot of time, money and physical 
effort but also lead to increased economic burden of 
disease. 
CONSTRAINTS IN OCULAR DRUG 
DELIVERY 
Eye is protected by a barrage of mechanisms and a large 
amount of drug is lost with topical instillation due to 
reasons such as; poor corneal penetration, loss of drug 
via conjunctival absorption, nasolacrimal drainage, 
precorneal metabolism, reflex blinking, tear dilution, 
etc. Rapid removal of drug from the site of absorption 
leads to less than 2% of the amount of drug that is 
administered being absorbed leading to decreased ocular 
bioavailability of a drug
1,3
. Other conventional dosage 
forms such as ointments and suspensions though 
available are not favored as much due to eye irritation 
and blurring of vision associated with them. 
DRUG DELIVERY ALTERNATIVES 
FOR OCULAR DELIVERY 
A leap in the science of novel drug delivery systems has 
led to invent of various types of drug delivery systems. 
The novel systems used in ocular drug delivery have 
proven to be advantageous in overcoming the ocular 
barriers and attend to problems associated with patient 
compliance and low ocular bioavailability of medicinal 
agents. Various drug delivery systems have been 
presented at a glance (Table 3). 
 
Table 3: Aspects of Novel Drug Delivery Systems 
Novel Drug 
Delivery System 
Composition Advantages 
Ocular inserts
23,26 
Made up of soluble/insoluble polymers. 
Drug is either dispersed in polymer matrix or 
soaked into the insert 
Increased residence time of formulation 
No frequent dosing of drug 
Accuracy of drug 
In-situ gelling 
systems
24,26
 
The formulation is incorporated with gelling 
agents 
Formulation can either be a solution of drug or a 
carrier based system 
Ease of application; similar to eye drops 
 
Upon instillation in eye, sol to gel transition 
occurs; leading to slow release of drug from 
polymeric matrix. 
Carrier based 
systems
3,4,24,25 
Nanoparticles: colloidal particles composed of 
either polymers or surfactant molecules. Drug is 
entrapped within the polymer matrix. 
Lipid based systems: vesicular systems, mimic 
natural cell membrane thus highly compatible 
 
Sustained drug delivery due to penetration of 
ocular barriers 
Surface modification by use of mucoadhesive 
leads to enhanced efficacy 
Non-toxic, biocompatible, non-immunogenic 
and biodegradable 
Implants
24 
Biodegradable or non-biodegradable implants  
placed into vitreous cavity 
Though the process is invasive, but sustained 
drug delivery can be extended up to few years 
thus ensuring good therapeutic outcome 
 
NIOSOMES IN OCULAR DRUG DELIVERY 
These are bilayered, lamellar structures primarily 
composed of non ionic surfactants and a rigidizing agent 
which are hydrated by different methods in order to 
form a vesicle. They are either unilamellar or 
multilamellar enclosing an aqueous compartment. Being 
amphiphilic in nature, the non ionic surfactants are 
known to possess the ability to self assemble. Critical 
parameters in niosome preparation govern the formation 
of vesicular structures instead of micelles
4,26-27
. The 
surfactants being non-ionic in nature do not cause any 
irritation to the ocular tissue and their ability to act as 
penetration enhancers can also be exploited. 
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Advantages of Niosomes Pertaining to Ocular 
Delivery: 
i. Size: It usually lies in nm range, easily tolerated 
by eyes as opposed to microparticulate systems
28
. 
ii. Stability: Non ionic surfactants are stable, not 
prone to oxidation etc., leakage of drugs as seen 
in liposomes is circumvented
4,26
. 
iii. Ease of handling: The components do not have 
any special handling problems
4,28.
 
iv. Cost effectiveness: It is one of the less expensive 
carrier systems
29
. 
v. Storage: The storage conditions are more flexible 
with niosomes because of use of non ionic 
surfactants
27,28,30
. 
vi. Biodegradability, biocompatibility and relative 
non-toxicity is observed
4,29
. 
vii. Versatility: It is successful in entrapping water 
soluble and water insoluble drugs
28,30
. 
viii. Osmotically active and stable28,30. 
ix. Prevent ocular metabolism of drugs by lachrymal 
fluid
27,30
. 
Composition of Niosomes 
These vesicular systems are essentially alternatives to 
liposomes. The non ionic surfactants possess versatility 
and ease of handling thus are easy to fabricate. Other 
than surfactants, membrane additives are also used in 
preparation, to enhance the properties of these systems 
and ensure good outcomes. The various materials used 
are described hereunder:  
Non-ionic Surfactants: They usually contain a 
hydrophobic tail and a hydrophilic head group and have 
ability to self assemble. HLB values of these surfactants 
play an important role in their ability to form vesicles. 
Various classes of non ionic surfactants that are used to 
form niosomes are given as follows
26-27, 30-31
: 
i. Ether linked surfactants: these include alkyl ethers 
and alkyl glyceryl ethers which have high stability. 
Some of the examples are: Brij 30, Brij 58, Brij 
72. 
ii. Sorbitan fatty acid esters: the esters which are 
formed upon interaction of plain sorbitan with 
fatty acids are called Spans. There are different 
varieties on basis of chain length of fatty acids; 
such as Span 20, Span 40, Span 60 and Span 80. 
They are widely used for preparation of niosomes.  
iii. Polyoxyethylene fatty acid esters: these include 
water soluble surfactants, and are liquid in nature 
formed by interaction between PEGy-lated 
sorbitan esterified with fatty acids. The examples 
include: Tween 20, Tween 80 and Tween 28 etc. 
iv. Others: few non ionic surfactants such as Bola 
surfactant, Gemini surfactant and Solulan C24 
have also been evaluated for preparation of 
niosomes. 
Membrane Stabilizing Agent: Cholesterol is 
incorporated with non ionic surfactants in order to form 
vesicles. Addition of cholesterol helps in stabilizing the 
bilayer that is formed prevents the phase transition 
changes of surfactants thus forming niosomes which are 
less leaky in nature
29- 30
.  
Charge Inducing Agents: these may be incorporated in 
the formulation in order to prevent aggregation of the 
formed vesicles thus diminish any instability that may 
so exist. Examples include Dicetylphosphate, 
Stearylamine, Cetylpyridinum chloride, etc.,
27, 29
. 
FABRICATION OF OCULAR ANTI-
HYPERTENSIVE AGENTS INTO NIOSOMES 
A lot of research has been conducted to develop novel 
niosomal drug delivery systems for management of 
glaucoma. Different classes of drugs have been 
formulated as niosomes and the results have shown 
effective drug delivery, prolonged duration of action and 
reduced systemic side effects. Few of the examples are 
listed below: 
 Acetazolamide: It is prescribed orally for treatment 
of glaucoma and accompanied with a plethora of 
systemic side effects. The limited solubility and 
permeability encountered with the drug further 
raises difficulty in developing a topical 
preparation
32
. Niosomes have been developed for 
this drug
33-35
. In a research, methods of preparation 
and charge inducers were varied and bioadhesives 
were also used to enhance efficacy. It was observed 
that reverse phase evaporation yielded niosomes 
with highest entrapment efficiency and those with 
bioadhesive coating were known to prolong the IOP 
lowering effect of the formulation
33
. Use of PEG 
400 in preparation of niosomes was investigated for 
its action on solubility of drug and penetration 
enhancement. Ocular bioavailability increased and 
IOP lowering effect was rapid
36
. 
 Timolol maleate: Use of mucoadhesive agents for 
prolonging the residence time of the niosomal 
formulations has been well documented. In one 
such niosomal formulation of Timolol maleate, 
various agents such as Chitosan, Carbopol 934P and 
Carbopol 974P were used to coat the surface of 
niosome. Pharmacodynamic effect was evaluated, 
chitosan coated timolol maleate significantly 
reduced IOP for a prolonged duration of 8 h and 
also a reduction in overall side effects was 
observed
37
. Ocular absorption profile was evaluated 
and results indicated that peak concentration of drug 
in aqueous humor is 1.7 times more than that seen 
with pure drug solution leading to enhanced 
efficacy
38
.  
 Brimonidine tartrate: Comparative study by 
preparing liposomes and niosomes was conducted, 
results predicted better drug release profile, stability 
profile and increased in-vivo IOP lowering effect of 
niosomes [39]. Coating of niosomes of the drug by 
Carbopol 940 was done, duration of action was 
found to have been extended up to 8 h where 
substantial decrease in IOP was observed and also 
no evidence of potential irritancy to eyes was 
observed
40
. 
 Ocular Gel: In-situ gelling systems were also 
developed using niosomes of brimonidine tartrate 
prepared by thin film hydration. Polymers used for 
gelling were carbopol 940 and HPMC K15M (in a 
definite ratio) in acetate buffer. The niosomes upon 
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instillation into eye formed a gel like matrix and gel 
exhibited pseudoplastic rheology. Gel 
systemshowed extended action up to 8 h
41
. 
Niosomal hydrogel of atenolol was formulated 
using various polymers (chitosan, carbopol 934P, 
sodium alginate). Atenolol/Carbopol hydrogel 
showed best result with 4.33 fold increase in AUC 
after 8 h of administration
42
. 
 Combination Dosage Form: Niosomes were 
prepared by thin film hydration technique using by 
using brimonidine tartrate and timolol maleate. 
Additive effect was observed in the IOP lowering 
activity of the combination. The in-vivo IOP 
lowering activity was also compared with 
Combigen (marketed formulation) and it was 
observed that there was a rise in IOP 4 h after 
administration of Combigen whereas niosomal 
preparations showed as much as 12 mmHg 
reduction in IOP after 6 h of administration
43
. 
CONCLUSION 
Glaucoma is on the rise and being a life-long condition, 
it demands daily use of medications in order to stall the 
nerve damage that occurs. Dosage forms which can 
prolong duration of action of drugs must be developed. 
In such situations niosomes present as a competent 
solution that not only have enhanced efficacy and 
stability but also minimum side effects. They exhibit 
increased ocular bioavailability of both hydrophilic and 
lipophilic drugs. Biocompatibility and biodegradability 
of these systems further outline their utility in drug 
delivery. Thus niosomes can be further probed in this 
regard and an effective drug delivery system be 
designed. 
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